MedTrace Logo

Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke

NCT02446977 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-10-13

No results posted yet for this study

Summary

Administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic stroke to know if it causes a reduction of glutamate-mediated excitotoxicity.

Conditions

Interventions

DRUG

Vitamin B2 Streuli®

4ml IV

OTHER

Solution for injection

4ml IV

Sponsors & Collaborators

  • Castillo, José, M.D.

    lead INDIV

Principal Investigators

  • José Castillo, MD · Complejo Hospitalario Universitario de Santiago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02446977 on ClinicalTrials.gov